174 related articles for article (PubMed ID: 31999063)
21. Assessment of provider practices regarding venous thromboembolism management and prevention in pediatric acute leukemia patients.
Degliuomini M; Cooley V; Mauer E; Gerber LM; Acharya S; Kucine N
J Thromb Thrombolysis; 2021 Jul; 52(1):209-213. PubMed ID: 33486673
[TBL] [Abstract][Full Text] [Related]
22. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin.
Elliott MA; Wolf RC; Hook CC; Pruthi RK; Heit JA; Letendre LL; Tefferi A; Kaufmann SH; Mesa RA; Litzow MR
Leuk Lymphoma; 2004 Aug; 45(8):1545-9. PubMed ID: 15370205
[TBL] [Abstract][Full Text] [Related]
23. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
Farrell K; Fyfe A; Allan J; Tait RC; Leach M
Leuk Lymphoma; 2016 Nov; 57(11):2568-74. PubMed ID: 27078747
[TBL] [Abstract][Full Text] [Related]
24. [Cerebral sinovenous thrombosis and acquired antithrombin, protein C and S deficiency during chemotherapy in a young man: report of a case].
Munoz VT; Triffet A; Cauchie P; Brohée D
Rev Med Brux; 2008; 29(6):535-9. PubMed ID: 19202708
[TBL] [Abstract][Full Text] [Related]
25. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment.
Nowak-Göttl U; Kenet G; Mitchell LG
Best Pract Res Clin Haematol; 2009 Mar; 22(1):103-14. PubMed ID: 19285277
[TBL] [Abstract][Full Text] [Related]
26. Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation.
Freyer CW; Carulli A; Ganetsky A; Hughes ME; Krause TM; Timlin C; Frey NV; Gill SI; Hexner EO; Loren AW; Mangan JK; Martin ME; McCurdy SR; Perl AE; Pratz K; Porter DL; Luger SM
Leuk Lymphoma; 2020 Sep; 61(9):2200-2207. PubMed ID: 32482107
[TBL] [Abstract][Full Text] [Related]
27. Thrombosis in children with acute lymphoblastic leukemia treated at a tertiary care center in Lebanon: revisiting the role of predictive models.
Al-Aridi C; Abboud MR; Saab R; Eid D; Jeha S; Chan AK; Muwakkit SA
Pediatr Hematol Oncol; 2011 Nov; 28(8):676-81. PubMed ID: 21787123
[TBL] [Abstract][Full Text] [Related]
28. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
29. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.
Mitchell L; Andrew M; Hanna K; Abshire T; Halton J; Wu J; Anderson R; Cherrick I; Desai S; Mahoney D; McCusker P; Chait P; Abdolell M; de Veber G; Mikulis D
Thromb Haemost; 2003 Aug; 90(2):235-44. PubMed ID: 12888870
[TBL] [Abstract][Full Text] [Related]
30. Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
Chen R; Liu X; Law AD; Kanfar S; Maze D; Chan SM; Gupta V; Yee KW; Minden MD; Schimmer AD; Schuh AC; McNamara CJ; Murphy T; Xu A; Falcone U; Seki J; Sibai H
Curr Oncol; 2020 Dec; 28(1):128-137. PubMed ID: 33704181
[TBL] [Abstract][Full Text] [Related]
31. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
Ruud E; Holmstrøm H; de Lange C; Natvig S; Albertsen BK; Wesenberg F
Pediatr Hematol Oncol; 2006; 23(3):207-16. PubMed ID: 16517537
[TBL] [Abstract][Full Text] [Related]
32. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia.
Andrew M; Brooker L; Mitchell L
Blood Coagul Fibrinolysis; 1994 Jan; 5 Suppl 1():S24-36; discussion S59-64. PubMed ID: 8186353
[TBL] [Abstract][Full Text] [Related]
33. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia.
Beinart G; Damon L
Am J Hematol; 2004 Dec; 77(4):331-5. PubMed ID: 15551293
[TBL] [Abstract][Full Text] [Related]
34. A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management.
Andersson NG; Rathe M; Mølle I; Jarvis KB; Hoffmann M; Huurre A; Joelsson J; Albertsen BK; Lohi O; Långström S; Overgaard U; Saulyte Trakymiene S; Vepsäläinen K; Vogt H; Ranta S
Br J Haematol; 2022 Oct; 199(1):117-121. PubMed ID: 35922061
[TBL] [Abstract][Full Text] [Related]
35. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
[TBL] [Abstract][Full Text] [Related]
36. L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia.
Merlen C; Bonnefoy A; Wagner E; Dedeken L; Leclerc JM; Laverdière C; Rivard GE
Pediatr Blood Cancer; 2015 Aug; 62(8):1381-7. PubMed ID: 25820776
[TBL] [Abstract][Full Text] [Related]
37. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.
Martin KA; Beyer-Westendorf J; Davidson BL; Huisman MV; Sandset PM; Moll S
J Thromb Haemost; 2021 Aug; 19(8):1874-1882. PubMed ID: 34259389
[TBL] [Abstract][Full Text] [Related]
38. Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study.
George G; Rezazadeh A; Zook F; Pearl N; McCoy C; Carlson K; Runaas L; Abedin S; Guru Murthy GS; Michaelis LC; Atallah E; Baumann-Kreuziger L
Leuk Res; 2020 Jul; 94():106368. PubMed ID: 32442786
[No Abstract] [Full Text] [Related]
39. Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.
Persson L; Harila-Saari A; Hed Myrberg I; Heyman M; Nilsson A; Ranta S
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28440015
[TBL] [Abstract][Full Text] [Related]
40. Cerebral Thrombotic Complications Related to l-Asparaginase Treatment for Acute Lymphoblastic Leukemia: Retrospective Review of 10 Cases.
Eden D; Hipkins R; Bradbury CA
Clin Appl Thromb Hemost; 2016 Sep; 22(6):589-93. PubMed ID: 25693917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
